

that contracted with Guardian Medical Direction to provide a medical director for the business, which offered services such as intravenous (“IV”) therapy, intramuscular (“IM”) injections, and cosmetic injections.

7. Respondent’s role as medical director of Bijou Blu primarily consisted of approving written standing orders/protocols that directed patient care at Bijou Blu and answering questions from employees.

8. While Respondent was medical director, she never communicated directly with its employees.

9. Respondent never examined patients or provided patient care while she was medical director. All patient care at Bijou Blu was provided by registered nurses (“RN”).

10. Respondent did not supervise the RNs who provided patient care at Bijou Blu while she was medical director.

11. On June 7, 2022, Respondent approved a standing order titled “Vitamin B12 Protocol” that authorizes RNs to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and administer Vitamin B12 IM injections to patients.

12. On June 7, 2022, Respondent approved a standing order titled “NAD+ IV Protocol” that authorizes RNs to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and initiate and manage Nicotinamide Adenine Dinucleotide IV infusion therapy.

13. On June 10, 2022, Respondent approved standing orders titled “IV Hydration Protocol” and “IV Hydration Standard Operation Procedure” that authorize RNs to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and initiate and manage

IV infusion therapy and administer IM injections. The standing orders also allow patients to choose their preferred medication from a menu.

14. On July 20, 2023, Respondent approved a standing order titled “Guardian Medical Direction Semaglutide Protocol” that authorizes RNs to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and administer semaglutide IM injections to patients.

15. On or about July 2023, Respondent approved a standing order titled “Neuromodulator Protocol” that authorizes RNs to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and administer injections of neuromodulators such as Botox and Xeomin to patients.

16. Each of the standing orders described in paragraphs 11-15 allowed RNs to initiate and administer treatment, even if the patient had not been examined or evaluated by a physician or a practitioner with prescribing authority and established a physician-patient relationship.

17. Each of the standing orders described in paragraphs 11-15 did not constitute valid prescriptions because they authorized RNs to exceed their scope of practice by making a medical diagnosis and developing and executing a treatment plan.

18. Respondent did not examine the patients, make a diagnosis, develop a treatment plan, or identify a clinical indication for the medications prescribed pursuant to the standing orders described in paragraphs 11-15.

19. On November 30, 2022, Respondent’s license lapsed and she did not renew it until December 13, 2022.

20. Four patients received IV infusions on December 2, 4, 9, and 10, 2023 at Bijou Blu pursuant to standing orders issued by Respondent in 2022.

21. In accordance with the standing orders, RNs conducted pre-treatment evaluations, assessed the patients, developed treatment plans, and administered the IV therapy treatment.

22. Respondent did not participate in the or supervise the RNs provision of the patients' treatment.

23. Bijou Blu purchased compounded drugs for patients' IV therapy treatments from Olympia Compounding Pharmacy.

24. In order for Bijou Blu to purchase compounded drugs from Olympia, Respondent executed an "Agreement for Purchase of Office Compounded Use" on December 27, 2021. The Agreement identified the non-licensed owner of Bijou Blu as the practitioner, but it was signed by Respondent and included her NPI and DEA registration number.

25. The agreement included a "Physician Statement Regarding Office Visit Requirements" which Respondent executed and agreed that a physical, in person, examination will be performed by the prescribing physician who will determine some logical connection exists between the complaint, medical history, the physical examination, and the drug prescribed prior to sending a prescription to Olympia.

26. The explicit purpose of the Physician Statement was to ensure that prescriptions received by Olympia were issued pursuant to a valid physician-patient relationship.

27. Respondent did not examine any patients at Bijou Blu while she was its medical director and issued prescriptions that were filled by Olympia. Instead, those patients were examined by RNs.

28. Respondent did not establish a physician-patient relationship with any patients at Bijou Blu for whom she issued prescriptions that were filled at Olympia.

29. As part of the investigation, a Board investigator visited Bijou Blu and spoke with an RN who was administering IV therapy treatment to a patient.

30. The RN showed the investigator a binder containing Bijou Blue standing orders for the administration of IV therapy treatment.

31. The binder contained a form from Legere Pharmaceuticals that includes a template prescription form used to order medications from the Olympia Pharmacy. The prescription was signed by Respondent but did not include any patient information. It also had blank spaces to identify the prescribed medication.

32. Respondent cooperated with the Committee's investigation and provided relevant documents and information to the Committee.

Conclusions of Law

33. Respondent failed to conform to essential standards of acceptable and prevailing practice when she issued prescriptions to patients pursuant to standing orders without examining them, making a diagnosis, developing a treatment plan, or identifying a clinical indication for the medications in violation of 26 V.S.A. § 1354(b)(2).

34. Respondent's issuance of four prescriptions for medications between November 30, 2022 and December 13, 2022 when she did not have a license constituted the unlicensed practice of medicine in violation of 26 V.S.A. § 1314(a).

35. Respondent's violations of 26 V.S.A. § 1314(a) are also failures to comply with the provisions of Vermont statutes governing the practice of medicine and constitute unprofessional conduct. 26 V.S.A. § 1354(a)(27).

36. Respondent made and filed false reports when she issued prescriptions to be filled by Olympia Pharmacy without first conducting physical, in-person patient examinations and determining that the medications were clinically indicated in violation of 26 V.S.A. § 1354(a)(8).

37. It is unprofessional conduct to sign a blank or undated prescription form. 26 V.S.A. § 1354(a)(38). Respondent engaged in unprofessional conduct when she signed a blank prescription form from Legere Pharmaceuticals.

38. It is also unprofessional conduct for a physician to delegate professional responsibilities to a person whom she knows is not qualified by training, experience, education, or licensing credentials to perform them. 26 V.S.A. § 1354(a)(29).

39. Respondent's issuance of standing orders that delegated to RNs the authority to conduct a pre-treatment evaluation, make an assessment, develop a treatment plan, and administer IV and IM prescription medications violated 26 V.S.A. § 1354(a)(29) and constitutes unprofessional conduct.

40. Respondent permitted Bijou Blu to use her name and license to open an account with and order medication from Olympia Pharmacy when she was not in charge of or responsible for the treatment provided by Bijou Blu in violation of 26 V.S.A. § 1354(a)(21).

41. Consistent with Respondent's cooperation with the Board, she acknowledges that if the State were to file charges it could satisfy its burden at a hearing and a finding adverse to her could be entered by the Board pursuant to 26 V.S.A. §§ 1354(a)(8), (21), (27), (29), (38), and (b)(2).

42. Respondent agrees that the Board may adopt as its facts and conclusions in this matter Paragraphs 1-41 and further agrees that this is an adequate basis for the Board actions set

forth herein. Any representation by Respondent herein is made solely for the purposes set forth in this agreement.

43. Therefore, in the interest of Respondent's desire to fully and finally resolve the matter presently before the Board, she has determined that she shall enter into this agreement with the Board. Respondent enters no further admissions here, but to resolve this matter without further time, expense, and uncertainty she has concluded that this agreement is acceptable and in the best interest of the parties.

44. Respondent agrees and understands that by executing this document she is waiving any right to challenge the jurisdiction and continuing jurisdiction of the Board in this matter, to be presented with a specification of charges and evidence, to cross-examine witnesses, and to offer evidence of her own to contest any allegations by the State.

45. The parties agree that upon the Board's acceptance of this Stipulation and Consent Order, and pursuant to the terms herein, the above-captioned matter shall be resolved by the Board. Thereafter, the Board will take no further action as to this matter absent non-compliance with the terms and conditions of this document by Respondent.

46. This Stipulation and Consent Order is conditioned upon its acceptance by the Board. If the Board rejects any part of this document, the entire agreement shall be considered void. Respondent agrees that if the Board does not accept this agreement in its current form, she shall not assert in any subsequent proceeding any claim of prejudice from any such prior consideration. If the Board rejects any part of this agreement, none of its terms shall bind Respondent or constitute an admission of any of the facts of the alleged misconduct, it shall not be used against Respondent in any way, it shall be kept in strict confidence, and it shall be

without prejudice to any future disciplinary proceeding and the Board's final determination of any charge against Respondent.

47. Respondent acknowledges and understands that this Stipulation and Consent Order shall be a matter of public record, shall be entered in her permanent Board file, shall constitute an enforceable legal agreement, and may and shall be reported to other licensing authorities, including but not limited to the Federation of State Medical Boards Board Action Databank and the National Practitioner Data Bank. In exchange for the actions by the Board, as set forth herein, Respondent expressly agrees to be bound by all terms and conditions of this Stipulation and Consent Order.

48. The parties therefore jointly agree that should the terms and conditions of this Stipulation and Consent Order be deemed acceptable by the Board, it may enter an order implementing the terms and conditions herein.

ORDER

WHEREFORE, based on the foregoing and the consent of Respondent, it is hereby ORDERED that:

1. Respondent shall be REPRIMANDED for the conduct set forth above.
2. Respondent's medical license shall be CONDITIONED as follows:
 - a. No later than one year from the date of approval of this Stipulation and Consent Order, Respondent shall successfully complete comprehensive continuing medical education ("CME") courses that address: (a) ethics and professionalism; and (b) medical direction. Respondent shall seek prior approval, in writing, from the Committee for the CME courses. The courses must be live, in-person courses or live, interactive courses offered

remotely. Upon successful completion of the CME courses, Respondent shall provide the Committee with proof of attendance. Respondent shall also provide the Committee with brief written narratives of the CME courses that document what she learned from the courses and how she will apply that knowledge to her practice. Respondent shall provide proof of attendance and the written narratives to the Committee within 30 days of completion of each course. Respondent shall be solely responsible for all costs associated with the CME courses.

- b. If and when Respondent practices medicine in Vermont, she shall retain the services of a “practice monitor” for a minimum of three years, subject to the terms and conditions set forth in the attached “Practice Monitoring Agreement,” which is incorporated by reference and attached hereto as Exhibit A. The three- year practice monitoring requirement will not begin until the official “start date” as defined in the attached Practice Monitoring Agreement. Respondent shall comply with the terms and obligations of the Practice Monitoring Agreement. Respondent shall provide a copy of this Stipulation to the practice monitor. Respondent shall be responsible for ensuring that the practice monitor complies with the terms and obligations of the Practice Monitoring Agreement. The practice monitoring requirement shall not cease until the Committee has approved, in writing, Respondent's written request to end the monitoring. Respondent shall be solely responsible for all costs associated with the practice monitor. Respondent shall be responsible for ensuring that the

practice monitor's reports are timely submitted to the Committee.

c. Respondent shall notify the Committee if she practices medicine in Vermont and provide the name and location of the practice, the type of practice, and the scope of her duties at the practice. Respondent shall provide the notification to the Committee no later than the first day she engages in the practice.

3. Respondent shall pay an ADMINISTRATIVE PENALTY of \$10,000.00 pursuant to 26 V.S.A. § 1374(b)(1)(A)(iii). Payment shall be made to the "State of Vermont Board of Medical Practice" and shall be sent to the Vermont Board of Medical Practice at the following address: Vermont Board of Medical Practice, 280 State Drive, Waterbury, VT 05671-8300. The payment shall be due no later than six (6) months after this Stipulation and Consent Order is approved by the Board.


SIGNATURES

Dated at Plainfield, Vermont, this ___ day of August, 2025.



Gail Falk
Chair, Central Investigative Committee
Vermont Board of Medical Practice

Dated at Adrian, Michigan, this 27 day of August, 2025.


Melissa S. VanSickle, M.D.

APPROVED AS TO LEGAL FORM:


Dated at Montpelier, Vermont this 1st day of August, 2025.

/s/ Kurt A. Kuehl

Kurt A. Kuehl
Assistant Attorney General
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609-1001
(802) 828-1297
kurt.kuehl@vermont.gov

**AS TO MELISSA S. VANSICKLE, M.D.
APPROVED AND ORDERED
VERMONT BOARD OF MEDICAL PRACTICE**

Signed on Behalf of the Vermont Board of Medical Practice

By: 
Rick Hildebrant, M.D.
Chair, Vermont Board of Medical Practice

Vote documented in the Vermont Board of Medical Practice meeting
minutes, dated ___09/03/2025_____.

Dated: ___09/03/2025_____